Goldman Sachs Singular Genomics Ups IPO Target to $187M The San Diego-based DNA sequencing startup plans to offer 8.5 million shares at an IPO price between $20 and $22 per share, for a $1.5 billion valuation. Sequencing Startup Singular Genomics Files for $100M IPO The San Diego-based company, led by a raft of Illumina veterans, is planning to build a new sequencing platform to address genomic and multiomic analysis. Twist Bioscience Proposes $250M Public Offering Included in the offering — Twist Bioscience's third this year — are 75,000 shares of common stock offered by certain selling shareholders. Sema4 Raises $121M in Series C Financing Round BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors. Adaptive Biotechnologies to Raise $240M in Public Stock Offering The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder. Jan 24, 2020 Adaptive Biotechnologies Prices Public Offering of Stock Jan 21, 2020 Adaptive Biotechnologies Announces Preliminary FY19 Revenue Increase, $257M Stock Offering Sep 25, 2019 Thermo Fisher Scientific Prices $5.7B Senior Notes Offering Aug 20, 2019 10x Genomics Files for $100M IPO Feb 27, 2019 Danaher Prices $2.76B Offering of Common, Preferred Stock Dec 8, 2015 Goldman Sachs Upgrades Myriad, Agilent, and Thermo Fisher; Downgrades PerkinElmer, Danaher Dec 18, 2014 Goldman Sachs Downgrades Qiagen, Bruker Sep 2, 2014 Goldman Sachs, Leerink Initiate Coverage of T2 Biosystems Jun 23, 2014 Goldman Sachs Reinstates Neutral Rating for Agilent Jun 25, 2013 Goldman Sachs Upgrades Waters; Downgrades Agilent, Genomic Health Apr 23, 2013 Quest Enters into Agreement to Buy Back $450M of Stock Apr 11, 2013 Goldman Sachs Upgrades Quest, LabCorp, Downgrades Sigma-Aldrich Mar 28, 2013 T2 Biosystems Raises $40M Jan 16, 2013 Goldman Sachs Survey Finds Spending on Life Science Tools Remains Challenged by Funding, Fiscal Concerns Dec 6, 2012 Goldman Sachs Resumes Coverage of Danaher with Neutral Rating Nov 19, 2012 Goldman Sachs Upgrades Agilent, Bruker; Lowers Cepheid, LabCorp Oct 11, 2012 Goldman Sachs Initiates Coverage of Genomic Health with Neutral Rating Oct 9, 2012 Analysts, Investors 'Troubled' as Affymetrix's Preliminary Q3 Revenues Miss Estimates Premium Aug 7, 2012 Goldman Sachs Issues Buy Rating for Hologic, Noting Contributions from Gen-Probe Purchase Jul 27, 2012 In Brief This Week: BD; RainDance Technologies; Shimadzu; Complete Genomics, Ingenuity Systems; Gen9; Gentris; ACGT; BioFortuna Load More Breaking News Pediatric Medulloblastoma Subgroups May Benefit from Lower-Dose Radiation Therapy Space Radiation Shows Limited Effects on Mammalian Sperm DNA, Fertility Bluestar Genomics Sues Former Consultant, Ludwig Institute for Cancer Research Over IP Ownership New Products Posted to GenomeWeb: 10x Genomics, Swift Biosciences, Agilent Technologies, More In Brief This Week: Quantum-Si, TGen, Yale, and More People in the News: New Appointments at Invitae, PGDx, Oxford Nanopore, PacBio, More The Scan Fertility Fraud Found Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today. Ties Between Vigorous Exercise, ALS in Genetically At-Risk People Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports. Test Warning The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK. Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.